Amova Asset Management Americas Inc. Raises Holdings in Arcturus Therapeutics Holdings Inc. $ARCT

Amova Asset Management Americas Inc. grew its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 12.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,288,935 shares of the biotechnology company’s stock after acquiring an additional 262,347 shares during the quarter. Amova Asset Management Americas Inc. owned about 0.08% of Arcturus Therapeutics worth $17,648,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Hennion & Walsh Asset Management Inc. raised its stake in Arcturus Therapeutics by 206.5% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 240,303 shares of the biotechnology company’s stock valued at $1,473,000 after buying an additional 161,910 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Arcturus Therapeutics by 12.9% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,671,000 after purchasing an additional 262,347 shares during the last quarter. Heartland Advisors Inc. acquired a new stake in shares of Arcturus Therapeutics in the first quarter worth $1,976,000. Allspring Global Investments Holdings LLC acquired a new stake in Arcturus Therapeutics during the 1st quarter worth about $211,000. Finally, Castleview Partners LLC acquired a new position in Arcturus Therapeutics in the first quarter valued at approximately $130,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Weiss Ratings raised shares of Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $24.25.

Arcturus Therapeutics Price Performance

Shares of Arcturus Therapeutics stock opened at $5.97 on Tuesday. Arcturus Therapeutics Holdings Inc. has a 12 month low of $5.77 and a 12 month high of $24.17. The stock has a market capitalization of $169.67 million, a price-to-earnings ratio of -2.12 and a beta of 2.37. The business has a 50-day moving average of $7.17 and a 200 day moving average of $7.48.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Friday, May 8th. The biotechnology company reported ($0.95) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.08. The company had revenue of $2.06 million for the quarter, compared to analysts’ expectations of $6.30 million. Arcturus Therapeutics had a negative return on equity of 36.55% and a negative net margin of 143.80%. Equities research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -3.99 earnings per share for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.